Global Viral and Non-Viral Vector Manufacturing Market.pdf

res
Focus on Vector Type, Application,
Disease and Region
Analysis and Forecast: 2021-2031
December 2021
Global Viral and
Non-Viral Vector
Manufacturing
Market
Table of Content

1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2021 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

2
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Table of Content
Executive Summary..........................................................................26
1. Product Definition......................................................................36
1.1 Product Definition............................................................................................36
2. Scope of Study...........................................................................37
2.1 Overview...........................................................................................................37
2.2 Segmentation of the Global Viral and Non-Viral Vector Manufacturing
Market ...............................................................................................................38
2.3 Assumptions and Limitations.........................................................................38
2.4 Key Questions Answered in This Report.......................................................39
2.5 Base Year and Forecast Period......................................................................40
3. Research Methodology ..............................................................41
3.1 Overview...........................................................................................................41
4. Global Viral and Non-Viral Vector Manufacturing: Market
Overview ...................................................................................47
4.1 Market Overview ..............................................................................................47
4.2 Introduction to Vectors ...................................................................................48
4.3 Importance of Vectors.....................................................................................49
4.3.1 Viral Vectors ................................................................................................50
4.3.2 Non-Viral Vectors ........................................................................................51
4.4 Major Milestones in Vector Manufacturing....................................................52
4.4.1 Manufacturing Process...............................................................................52
4.4.1.1 Upstream Bioprocessing.................................................................................... 52
4.4.1.2 Downstream Bioprocessing............................................................................... 53
4.5 Global Viral and Non-Viral Vector Manufacturing Market Size ....................54
4.6 Impact of COVID-19 on the Global Viral and Non-Viral Vector
Manufacturing Market .....................................................................................55
4.6.1 Disruption of the Vector Manufacturing Industry Due to COVID-19
Crisis ............................................................................................................55
4.6.2 COVID-19 Affecting the Supply Chain of Vector-Based Therapies.........57

3
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
4.6.2.1 Effect on Cell Therapy ....................................................................................... 58
4.6.2.2 Effect on Gene Therapy..................................................................................... 59
4.6.3 Interruption in Research and Clinical Development and Commercial
Operation .....................................................................................................60
4.6.3.1 Research and Clinical Development.................................................................. 60
4.6.3.2 Commercial Operation and Access ................................................................... 60
4.6.4 Effect of COVID-19 in Vaccine Manufacturing ..........................................61
4.6.5 Measures Taken to Address the Current Problem ...................................64
4.6.6 Navigating Crisis Recovery and Looking to the Future...........................65
5. Market Dynamics .......................................................................67
5.1 Impact Analysis ...............................................................................................67
5.2 Overview...........................................................................................................67
5.3 Market Drivers..................................................................................................68
5.3.1 Viral Vectors ................................................................................................68
5.3.1.1 Rapid Uptake of Viral Vector to Develop Innovative Therapies......................... 68
5.3.1.2 Increasing Number of Clinical Studies for the Development of Gene
Therapy ................................................................................................... 69
5.3.1.3 Favorable Funding Scenario for Vector-Based Therapies................................. 70
5.3.2.1 Increasing Adoption of Nucleic Acid Therapeutics ............................................ 71
5.3.2.2 Rise in Synergistic Activities in the Market ........................................................ 71
5.4 Market Restraints.............................................................................................72
5.4.1 Viral Vectors ................................................................................................72
5.4.1.1 Unaffordable Cost of Gene Therapy.................................................................. 72
5.4.1.2 High Manufacturing Cost of Viral Vectors.......................................................... 73
5.4.1.3 Complications Associated with Large-Scale Production of Viral Vectors .......... 74
5.4.2.1 Low Transfection Efficiency............................................................................... 74
5.5 Market Opportunities.......................................................................................75
5.5.1 Viral Vectors ................................................................................................75
5.5.1.1 Rise in Demand for Synthetic Genes................................................................. 75
5.5.1.2 Emergence of Next-Generation Vectors............................................................ 75

4
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
5.5.2.1 Limitation of Viral Vectors.................................................................................. 76
6. Industry Analysis .......................................................................77
6.1 Overview...........................................................................................................77
6.2 Regulatory Scenario........................................................................................79
6.3 Patent Landscape............................................................................................82
7. Competitive Landscape .............................................................86
7.1 Overview...........................................................................................................86
7.2 Key Development and Strategies...................................................................87
7.2.1 Synergistic Activities ..................................................................................88
7.2.2 Business Expansion ...................................................................................89
7.2.3 Product Launches .......................................................................................90
7.2.4 Mergers and Acquisitions...........................................................................90
7.2.5 Other Development .....................................................................................91
7.3 Market Share Analysis (by Company), 2020..................................................92
7.4 Growth Share Analysis ...................................................................................94
7.4.1 Growth Share Analysis of the Global Viral and Non-Viral Vector
Manufacturing Market (by Company) ........................................................94
7.4.2 Growth Share Analysis of the Global Viral and Non-Viral Vector
Manufacturing Market (by Vector Type) ....................................................95
8. Global Viral and Non-Viral Vector Manufacturing Market (by
Vector Type)..............................................................................97
8.1 Overview...........................................................................................................97
8.2 Viral Vector.......................................................................................................99
8.2.1 Adenoviral Vector......................................................................................102
8.2.2 Retroviral Vector........................................................................................104
8.2.3 Adeno-Associated Viral Vector ................................................................105
8.2.4 Lentiviral Vector ........................................................................................106
8.2.5 Vaccinia Viral Vector.................................................................................108
8.2.6 Other Viral Vector......................................................................................109

5
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
8.3 Non-Viral Vectors...........................................................................................110
8.3.1 Plasmid DNA..............................................................................................111
8.3.2 Lipid-Based Non-Viral Vector...................................................................113
8.3.3 Polymer-Based Non-Viral Vector .............................................................114
8.3.4 Other Non-Viral Vector (Peptide-Based and Hybrid/Combination) .......116
Disease) ..................................................................................118
9.1 Overview.........................................................................................................118
9.2 Cancer ............................................................................................................120
9.3 Genetic Disease.............................................................................................122
9.4 Infectious Disease .........................................................................................123
9.5 Cardiovascular Disease ................................................................................125
9.6 Other Diseases...............................................................................................127
Application).............................................................................129
10.1 Overview.........................................................................................................129
10.2 Gene Therapy.................................................................................................131
10.2.1 Viral Vector ................................................................................................132
10.2.2 Non-Viral Vector ........................................................................................134
10.3 Vaccinology....................................................................................................136
10.3.1 Viral Vector ................................................................................................138
10.3.2 Non-Viral Vector ........................................................................................139
10.4 Cell Therapy ...................................................................................................140
10.4.1 Viral Vector ................................................................................................142
10.4.2 Non-Viral Vector ........................................................................................143
10.5 Other Applications.........................................................................................144
10.5.1 Viral Vector ................................................................................................145
10.5.2 Non-Viral Vector ........................................................................................146
Region)....................................................................................147

6
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
11.1 Overview.........................................................................................................147
11.2 North America................................................................................................148
11.2.1 Overview ....................................................................................................148
11.2.2 U.S. .............................................................................................................149
11.2.2.1 Viral Vector ...................................................................................................... 151
11.2.2.2 Non-Viral Vector .............................................................................................. 152
11.2.3 Canada .......................................................................................................153
11.2.3.1 Viral Vector ...................................................................................................... 154
11.2.3.2 Non-Viral Vector .............................................................................................. 155
11.3 Europe ............................................................................................................156
11.3.1 Overview ....................................................................................................156
11.3.2 Germany.....................................................................................................157
11.3.2.1 Viral Vector ...................................................................................................... 158
11.3.2.2 Non-Viral Vector .............................................................................................. 159
11.3.3 U.K. .............................................................................................................160
11.3.3.1 Viral Vector ...................................................................................................... 161
11.3.3.2 Non-Viral Vector .............................................................................................. 162
11.3.4 France.........................................................................................................163
11.3.4.1 Viral Vector ...................................................................................................... 164
11.3.4.2 Non-Viral Vector .............................................................................................. 165
11.3.5 Italy .............................................................................................................166
11.3.5.1 Viral Vector ...................................................................................................... 167
11.3.5.2 Non-Viral Vector .............................................................................................. 168
11.3.6 Switzerland ................................................................................................168
11.3.6.1 Viral Vector ...................................................................................................... 170
11.3.6.2 Non-Viral Vector .............................................................................................. 171
11.3.7 Belgium ......................................................................................................171
11.3.7.1 Viral Vector ...................................................................................................... 173
11.3.7.2 Non-Viral Vector .............................................................................................. 173
11.3.8 Spain...........................................................................................................174
11.3.8.1 Viral Vector ...................................................................................................... 175

7
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
11.3.8.2 Non-Viral Vector .............................................................................................. 176
11.3.9 Rest-of-Europe...........................................................................................176
11.3.9.1 Viral Vector ...................................................................................................... 178
11.3.9.2 Non-Viral Vector .............................................................................................. 178
11.4 Asia-Pacific ....................................................................................................179
11.4.1 Overview ....................................................................................................179
11.4.2 China ..........................................................................................................180
11.4.2.1 Viral Vector ...................................................................................................... 182
11.4.2.2 Non-Viral Vector .............................................................................................. 182
11.4.3 Australia.....................................................................................................183
11.4.3.1 Viral Vector ...................................................................................................... 185
11.4.3.2 Non-Viral Vector .............................................................................................. 185
11.4.4 Japan..........................................................................................................186
11.4.4.1 Viral Vector ...................................................................................................... 187
11.4.4.2 Non-Viral Vector .............................................................................................. 188
11.4.5 India............................................................................................................188
11.4.5.1 Viral Vector ...................................................................................................... 190
11.4.5.2 Non-Viral Vector .............................................................................................. 191
11.4.6 South Korea ...............................................................................................191
11.4.6.1 Viral Vector ...................................................................................................... 193
11.4.6.2 Non-Viral Vector .............................................................................................. 193
11.4.7 Singapore...................................................................................................194
11.4.7.1 Viral Vector ...................................................................................................... 195
11.4.7.2 Non-Viral Vector .............................................................................................. 196
11.4.8 Rest-of-Asia-Pacific...................................................................................196
11.4.8.1 Viral Vector ...................................................................................................... 197
11.4.8.2 Non-Viral Vector .............................................................................................. 198
11.5 Rest-of-the-World ..........................................................................................199
11.5.1 Overview ....................................................................................................199
11.5.1.1 Viral Vector ...................................................................................................... 200
11.5.1.2 Non-Viral Vector .............................................................................................. 201

8
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12. Company Profiles.....................................................................202
12.1 Overview.........................................................................................................202
12.2 Boehringer Ingelheim....................................................................................203
12.2.1 Company Overview ...................................................................................203
12.2.1.1 Role of Boehringer Ingelheim in the Global Viral and Non-Viral Vector
Manufacturing Market............................................................................ 203
12.2.1.2 Product Portfolio .............................................................................................. 203
12.2.2 SWOT Analysis..........................................................................................204
12.3 Catalent, Inc. ..................................................................................................205
12.3.1.1 Role of Catalent, Inc. in the Global Viral and Non-Viral Vector
12.3.2 Financials...................................................................................................207
12.3.3 Key Insights about Financial Health of the Company............................208
12.3.4 SWOT Analysis..........................................................................................209
12.4 FUJIFILM Holdings Corporation...................................................................210
12.4.1.1 Role of FUJIFILM Holdings Corporation in the Global Viral and Non-Viral
Vector Manufacturing Market ................................................................ 210
12.4.2 Financials...................................................................................................211
12.4.4 SWOT Analysis..........................................................................................214
12.5 Danaher Corporation.....................................................................................215
12.5.2 Role of Danaher Corporation in the Global Viral and Non-Viral
Vector Manufacturing Market ...................................................................215
12.5.3 Financials...................................................................................................217
12.5.5 SWOT Analysis..........................................................................................219

9
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.6 Genscript Biotech Corporation ....................................................................220
12.6.1.1 Role of Genscript Biotech Corporation in the Global Viral and Non-Viral
12.6.2 Financials...................................................................................................221
12.6.4 SWOT Analysis..........................................................................................224
12.7 Lonza Group AG ............................................................................................225
12.7.1.1 Role of Lonza Group AG in the Global Viral and Non-Viral Vector
12.7.2 Financials...................................................................................................226
12.7.4 SWOT Analysis..........................................................................................229
12.8 Merck KGaA Inc. ............................................................................................230
12.8.1.1 Role of Merck KGaA Inc. in the Global Viral and Non-Viral Vector
12.8.2 Financials...................................................................................................231
12.8.4 SWOT Analysis..........................................................................................233
12.9 Oxford Biomedica plc....................................................................................234
12.9.1.1 Role of Oxford Biomedica plc in the Global Viral and Non-Viral Vector
12.9.2 Financials...................................................................................................235
12.9.4 SWOT Analysis..........................................................................................238

10
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.10 Sartorius AG...................................................................................................239
12.10.1 Company Overview.............................................................................239
12.10.1.1 Role of Sartorius AG in the Global Viral and Non-Viral Vector
12.10.2 Financials ............................................................................................240
12.10.3 Key Insights about Financial Health of the Company......................242
12.10.4 SWOT Analysis....................................................................................243
12.11 Takara Bio Inc. ...............................................................................................244
12.11.1.1 Role of Takara Bio Inc. in the Global Viral and Non-Viral Vector
12.11.2 Financials ............................................................................................245
12.11.4 SWOT Analysis....................................................................................248
12.12 Thermo Fisher Scientific Inc.........................................................................249
12.12.1.1 Role of Thermo Fisher Scientific, Inc. in the Global Viral and Non-Viral
12.12.2 Financials ............................................................................................251
12.12.4 SWOT Analysis....................................................................................253
12.13 Wuxi AppTec..................................................................................................254
12.13.1.1 Role of Wuxi AppTec in Global Viral and Non-Viral Vector Manufacturing
Market.................................................................................................... 254
12.13.2 Financials ............................................................................................255
12.13.4 SWOT Analysis....................................................................................258

11
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.14 Acuitas Therapeutics ....................................................................................259
12.14.1.1 Role of Acuitas Therapeutics in the Global Viral and Non-Viral Vector
12.14.2 SWOT Analysis....................................................................................260
12.15 Evonik Industries AG ....................................................................................261
12.15.1.1 Role of Evonik Industries AG in the Global Viral and Non-Viral Vector
12.15.2 Financials ............................................................................................262
12.15.4 SWOT Analysis....................................................................................265
12.16 Exelead, Inc....................................................................................................266
12.16.1.1 Role of Exelead, Inc. in the Global Viral and Non-Viral Vector
12.16.2 SWOT Analysis....................................................................................267
12.17 Entos Pharmaceuticals .................................................................................268
12.17.1.1 Role of Entos Pharmaceuticals in the Global Viral and Non-Viral Vector
12.17.2 SWOT Analysis....................................................................................269
12.18 Genevant Sciences GmbH ............................................................................270
12.18.1.1 Role of Genevant Sciences GmbH in the Global Viral and Non-Viral
12.18.2 SWOT Analysis....................................................................................271

12
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
12.19 T&T Scientific Corporation ...........................................................................272
12.19.1.1 Role of T&T Scientific Corporation in the Global Viral and Non-Viral
12.19.2 SWOT Analysis....................................................................................273
12.20 Moderna, Inc...................................................................................................274
12.20.1.1 Role of Moderna, Inc. in the Global Viral and Non-Viral Vector
12.20.2 Financials ............................................................................................276
12.20.4 SWOT Analysis....................................................................................278
12.21 CureVac N.V. ..................................................................................................279
12.21.1.1 Role of CureVac N.V in the Global Viral and Non-Viral Vector
12.21.2 Financials ............................................................................................280
12.21.4 SWOT Analysis....................................................................................282

13
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
List of Figures
Figure 1: Global Viral and Non-Viral Vector Manufacturing Market (by Region), 2020 and 2031
Figure 2: Key Players of the Global Viral and Non-Viral Vector Manufacturing Market
Figure 3: Drivers, Challenges, and Opportunities of the Global Viral Vector and Non-Viral Vector
Manufacturing Market
Figure 4: Share of Key Developments and Strategies, January 2018-October 2021
Figure 5: Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), $Million, 2020
and 2031
Figure 6: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 7: Global Viral and Non-Viral Vector Manufacturing Market (by Disease), 2020 and 2031
Figure 8: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
Figure 9: Global Viral and Non-Viral Vector Manufacturing Market Segmentation
Figure 10: Global Viral and Non-Viral Vector Manufacturing Market Research Methodology
Figure 11: Primary Research
Figure 12: Secondary Research
Figure 13: Data Triangulation
Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
Figure 15: Top-Down Approach (Segment-Wise Analysis)
Figure 16: Assumptions and Limitations
Figure 17: Mechanism of Action of Vectors
Figure 18: Evolutionary History of Vectors
Figure 19: Typical Production Methods of Viral Vectors and Plasmids
Figure 20: Global Viral and Non-Viral Vector Manufacturing Market, $Billion, 2020-2031
Figure 21: Pre- COVID-19 and Post-COVID-19 Scenario of the Global Viral and Non-Viral Vector
Manufacturing Market, 2017-2025
Figure 22: Long, Complex, and Highly Controlled Supply Chain of Cell Therapy
Figure 23: Less-Complex Supply Chain of Gene Therapy
Figure 24: Areas of Disruption in Cell Therapy Industry
Figure 25: Areas of Disruption in Gene Therapy Industry
Figure 26: Key Areas of Disruption in Commercial Operation
Figure 27: Measures to Navigate Crisis Recovery
Figure 28: Impact Analysis
Figure 29: Workflow Associated with Biomanufacturing for the Commercialization of Viral and Non-
Viral Vector Products
Figure 30: Competitive Landscape, January 2018-October 2021
Figure 31: Share of Key Development and Strategy, January 2018-October 2021
Figure 32: Share of Synergistic Activities (by Company), January 2018-October 2021

14
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 33: Share of Business Expansion Activities (by Company), January 2018-October 2021
Figure 34: Share of Product Launches (by Company), January 2018-October 2021
Figure 35: Share of Mergers and Acquisitions (by Company), January 2018-October 2021
Figure 36: Share of Other Key Developments (by Company), January 2018-October 2021
Figure 37: Market Share Analysis of Global Viral and Non-Viral Vector Manufacturing Market (by
Company), 2020
Figure 38: Growth Share Analysis for Global Viral and Non-Viral Vector Manufacturing Market (by
Company), 2020
Figure 39: Growth Share Analysis for the Global Viral and Non-Viral Vector Manufacturing Market (by
Vector Type), 2020
Figure 40: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Vector Type)
Figure 41: Global Viral and Non-Viral Vector Manufacturing Market (by Viral and Non-Viral Vector),
$Million, 2020 and 2031
Figure 42: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020-
2031
Figure 43: Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 44: Global Viral and Non-Viral Vector Manufacturing Market for Adenoviral Vector $Million,
2020-2031
Figure 45: Global Viral and Non-Viral Vector Manufacturing Market for Retroviral Vector $Million, 2020-
2031
Figure 46: Global Viral and Non-Viral Vector Manufacturing Market for Adeno-Associated Viral Vector,
$Million, 2020-2031
Figure 47: Global Viral and Non-Viral Vector Manufacturing Market for Lentiviral Vector, 2020-2031
Figure 48: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinia Viral Vector, $Million,
2020-2031
Figure 49: Global Viral and Non-Viral Vector Manufacturing Market for Other Viral Vector, $Million,
2020-2031
Figure 50: Global Viral and Non-Viral Vector Manufacturing Market for Non-Viral Vectors, 2020-2031
Figure 51: Global Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 52: Global Viral and Non-Viral Vector Manufacturing Market for Plasmid DNA, $Million, 2020-
2031
Figure 53: Different Types of Lipid-Based Non-Viral Vectors
Figure 54: Viral and Non-Viral Vector Manufacturing Market for Lipid-Based Non-Viral Vectors,
$Million, 2020-2031
Figure 55: Different Types of Polymers Used as Delivery Systems
Figure 56: Viral and Non-Viral Vector Manufacturing Market for Polymer-Based Non-Viral Vector,
$Million, 2020-2031
Figure 57: Viral and Non-Viral Vector Manufacturing Market for Other Non-Viral Vector, $Million, 2020-
2031

15
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 58: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Disease)
Figure 59: Global Viral and Non-Viral Vector Manufacturing Market (by Disease)
Figure 60: Global Viral and Non-Viral Vector Manufacturing Market for Cancer, $Million, 2020-2031
Figure 61: List of Approved Human Gene Transfer Trials for Monogenic Disorders
Figure 62: Global Viral and Non-Viral Vector Manufacturing Market for Genetic Disease, $Million,
2020-2031
Figure 63: Global Viral and Non-Viral Vector Manufacturing Market for Infectious Disease, $Million,
2020-2031
Figure 64: Global Viral and Non-Viral Vector Manufacturing Market for Cardiovascular Disease,
$Million, 2020-2031
Figure 65: Global Viral and Non-Viral Vector Manufacturing Market for Other Diseases, 2020-2031
Figure 66: Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Application)
Figure 67: Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031
Figure 68: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy, $Million, 2020-
2031
Figure 69: Gene Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 70: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Viral Vector),
Figure 71: Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Non-Viral
Vector), $Million, 2020 and 2031
Figure 72: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology, $Million, 2020-
2031
Figure 73: Vaccinology: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 74: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Viral Vector),
Figure 75: Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Non-Viral
Vector), 2020 and 2031
Figure 76: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy, $Million, 2020-
2031
Figure 77: Cell Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 78: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Viral Vector),
Figure 79: Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Non-Viral
Figure 80: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications, $Million,
2020-2031
Figure 81: Other Applications: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 82: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Viral
Figure 83: Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Non-Viral

16
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 84: North America: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 85: U.S.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 86: U.S.: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-
2031
Figure 87: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and
2031
Figure 88: U.S.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020
and 2031
Figure 89: Canada: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 90: Canada: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 91: Canada: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 92: Canada: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 93: Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 94: Germany: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 95: Germany: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 96: Germany: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 97: Germany: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 98: U.K.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 99: U.K.: Viral Vs Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-
2031
Figure 100: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 101: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 102: France: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 103: France: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 104: France: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 105: France: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 106: Italy: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 107: Italy: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), 2020-2031
Figure 108: Italy: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031

17
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 109: Italy: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 110: Switzerland: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 111: Switzerland: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 112: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 113: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
Figure 114: Belgium: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 115: Belgium: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 116: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 117: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), 2020
and 2031
Figure 118: Spain: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 119: Spain: Viral and Non-Viral Vector Manufacturing Market, (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 120: Spain: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 121: Spain: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 122: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 123: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 124: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
Figure 125: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
Figure 126: Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 127: China: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 128: China: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 129: China: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 130: China: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 131: Australia: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 132: Australia: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031

18
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 133: Australia: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 134: Australia: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
Figure 135: Japan: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 136: Japan: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million,
2020-2031
Figure 137: Japan: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 138: Japan: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 139: India: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 140: India: Viral vs Non-Viral Vector Manufacturing Market, $Million, 2020-2031
Figure 141: India: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020
and 2031
Figure 142: India: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million,
2020 and 2031
Figure 143: South Korea: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020-
2031
Figure 144: South Korea: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 145: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
Figure 146: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
Figure 147: Singapore: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031
Figure 148: Singapore: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral),
$Million, 2020-2031
Figure 149: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million,
2020 and 2031
Figure 150: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector),
$Million, 2020-2031
Figure 151: Rest-of-Asia-Pacific: Viral Vector and Non-Viral Vector Manufacturing Market, $Million,
2020-2031
Figure 152: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-
Viral Vector), $Million, 2020-2031
Figure 153: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
Figure 154: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral
Figure 155: Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031

19
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 156: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-
Viral), $Million, 2020-2031
Figure 157: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector),
Figure 158: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral
Figure 159: Shares of Key Company Profiles
Figure 160: Boehringer Ingelheim: Service Portfolio
Figure 161: Boehringer Ingelheim: SWOT Analysis
Figure 162: Catalent, Inc.: Service/Product Portfolio
Figure 163: Catalent, Inc.: Overall Financials, $Million, 2019-2021
Figure 164: Catalent, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 165: Catalent, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 166: Catalent, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 167: Catalent, Inc.: SWOT Analysis
Figure 168: FUJIFILM Holdings Corporation: Service/Product Portfolio
Figure 169: FUJIFILM Holdings Corporation: Overall Financials, $Million, 2018-2020
Figure 170: FUJIFILM Holdings Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 171: FUJIFILM Holdings Corporation: Revenue (by Region), $Million, 2018-2020
Figure 172: FUJIFILM Holdings Corporation: R&D Expenditure, $Million, 2018-2020
Figure 173: FUJIFILM Holdings Corporation: SWOT Analysis
Figure 174: Danaher Corporation: Service/Product Portfolio
Figure 175: Danaher Corporation: Overall Financials, $Million, 2018-2020
Figure 176: Danaher Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 177: Danaher Corporation: Revenue (by Region), $Million, 2018-2020
Figure 178: Danaher Corporation: R&D Expenditure, $Million, 2018-2020
Figure 179: Danaher Corporation: SWOT Analysis
Figure 180: Genscript Biotech Corporation: Service/Product Portfolio
Figure 181: Genscript Biotech Corporation: Overall Financials, $Million, 2018-2020
Figure 182: Genscript Biotech Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 183: Genscript Biotech Corporation: Revenue (by Region), $Million, 2018-2020
Figure 184: Genscript Biotech Corporation: R&D Expenditure, $Million, 2018-2020
Figure 185: Genscript Biotech Corporation: SWOT Analysis
Figure 186: Lonza Group AG: Service/Product Portfolio
Figure 187: Lonza Group AG: Overall Financials, $Million, 2018-2020
Figure 188: Lonza Group AG: Revenue (by Segment), $Million, 2018-2020
Figure 189: Lonza Group AG: Revenue (by Region), $Million, 2018-2020
Figure 190: Lonza Group AG: R&D Expenditure, $Million, 2018-2020
Figure 191: Lonza Group AG: SWOT Analysis

20
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 192: Merck KGaA Inc.: Service/Product Portfolio
Figure 193: Merck KGaA Inc.: Overall Financials, $Million, 2018-2020
Figure 194: Merck KGaA Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 195: Merck KGaA Inc.: Revenue (by Region), $Million, 2018-2020
Figure 196: Merck KGaA Inc.: R&D Expenditure, $Million, 2018-2020
Figure 197: Merck KGaA Inc.: SWOT Analysis
Figure 198: Oxford Biomedica plc: Service/Product Portfolio
Figure 199: Oxford Biomedica plc: Overall Financials, $Million, 2018-2020
Figure 200: Oxford Biomedica plc: Revenue (by Segment), $Million, 2018-2020
Figure 201: Oxford Biomedica plc: Revenue (by Region), $Million, 2018-2020
Figure 202: Oxford Biomedica plc: R&D Expenditure, $Million, 2018-2020
Figure 203: Oxford Biomedica plc: SWOT Analysis
Figure 204: Sartorius AG: Service/Product Portfolio
Figure 205: Sartorius AG: Overall Financials, $Million, 2018-2020
Figure 206: Sartorius AG: Revenue (by Segment), $Million, 2018-2020
Figure 207: Sartorius AG: Revenue (by Region), $Million, 2018-2020
Figure 208: Sartorius AG: R&D Expenditure, $Million, 2018-2020
Figure 209: Sartorius AG: SWOT Analysis
Figure 210: Takara Bio Inc.: Service/Product Portfolio
Figure 211: Takara Bio Inc.: Overall Financials, $Million, 2018-2020
Figure 212: Takara Bio Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 213: Takara Bio Inc.: Revenue (by Region), $Million, 2018-2020
Figure 214: Takara Bio Inc.: R&D Expenditure, $Million, 2018-2020
Figure 215: Takara Bio Inc.: SWOT Analysis
Figure 216: Thermo Fisher Scientific, Inc.: Service/Product Portfolio
Figure 217: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020
Figure 218: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 219: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 220: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 221: Thermo Fisher Scientific, Inc.: SWOT Analysis
Figure 222: Wuxi AppTec: Service/Product Portfolio
Figure 223: Wuxi AppTec: Overall Financials, $Million, 2018-2020
Figure 224: Wuxi AppTec: Revenue (by Segment), $Million, 2018-2020
Figure 225: Wuxi AppTec: Revenue (by Region), $Million, 2018-2020
Figure 226: Wuxi AppTec: R&D Expenditure, $Million, 2018-2020
Figure 227: Wuxi AppTec: SWOT Analysis
Figure 228: Acuitas Therapeutics: Service/Product Portfolio
Figure 229: Acuitas Therapeutics: SWOT Analysis
Figure 230: Evonik Industries AG: Service/Product Portfolio

21
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Figure 231: Evonik Industries AG: Overall Financials, $Million, 2018-2020
Figure 232: Evonik Industries AG: Revenue (by Segment), $Million, 2018-2020
Figure 233: Evonik Industries AG: Revenue (by Region), $Million, 2018-2020
Figure 234: Evonik Industries AG: R&D Expenditure, $Million, 2018-2020
Figure 235: Evonik Industries AG: SWOT Analysis
Figure 236: Exelead, Inc.: Service/Product Portfolio
Figure 237: Exelead, Inc.: SWOT Analysis
Figure 238: Entos Pharmaceuticals: Service/Product Portfolio
Figure 239: Entos Pharmaceuticals: SWOT Analysis
Figure 240: Genevant Sciences GmbH: Service/Product Portfolio
Figure 241: Genevant Sciences GmbH: SWOT Analysis
Figure 242: T&T Scientific Corporation: Service/Product Portfolio
Figure 243: T&T Scientific Corporation: SWOT Analysis
Figure 244: Moderna, Inc.: Service/Product Portfolio
Figure 245: Moderna, Inc.: Overall Financials, $Million, 2018-2020
Figure 246: Moderna, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 247: Moderna, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 248: Moderna, Inc.: SWOT Analysis
Figure 249: CureVac N.V.: Product Portfolio
Figure 250: CureVac N.V.: Overall Financials, $Million, 2018-2020
Figure 251: CureVac N.V.: Revenue (by Region), $Million, 2018-2020
Figure 252: CureVac N.V.: R&D Expenditure, $Million, 2018-2020
Figure 253: CureVac N.V.: SWOT Analysis

22
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
List of Tables
Table 1: Leading Segments of the Global Viral and Non-Viral Vector Manufacturing Market, 2020
and 2031
Table 2: Advantages and Disadvantages of Viral Vectors
Table 3: Advantages and Disadvantages of Non-Viral Vectors
Table 4: COVID-19 Candidate Viral Vector Vaccines in Clinical Stage (as of 31st July 2020)
Table 5: COVID-19 Candidate Viral Vector Vaccines in Preclinical Stage (as of 31 July 2020)
Table 6: Recent Approvals for Gene Therapy
Table 7: Companies Offering Gene Therapies and Their Cost
Table 8: Global Regulatory Scenario
Table 9: Patents Related to Viral Vectors (January 2018-February 2021)
Table 10: Patents Related to Non-Viral Vectors (January 2018-February 2021)
Table 11: Examples of Viral Vectors Used in Gene Therapy
Table 12: List of Non-Viral Vector-Based Vaccines against Infectious Diseases
Table 13: Features of Vectors Used in Cardiovascular Therapy
Table 14: Examples of Clinical Trials Using Viral Vectors
Table 15: List of Clinical Trials Using Non-Viral Vectors
Table 16: Advantages and Disadvantages Associated with Major Viral Vectors

23
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

24
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

25
G
L
O
B
A
L
V
I
R
A
L
A
N
D
N
O
N
-
V
I
R
A
L
V
E
C
T
O
R
M
A
N
U
F
A
C
T
U
R
I
N
G
M
A
R
K
E
T
BIS RESEARCH INC.
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Global Viral and Non-Viral Vector Manufacturing Market.pdf

Recommended

Recommended

More Related Content

Similar to Global Viral and Non-Viral Vector Manufacturing Market.pdf

Similar to Global Viral and Non-Viral Vector Manufacturing Market.pdf (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Global Viral and Non-Viral Vector Manufacturing Market.pdf